In this study, we have reported the results of a clinical trial assessing the addition of TP-0903, an investigational multikinase inhibitor, to decitabine treatment for patients with AML with mutant TP53, complex karyotype, or both. The gene discussed is TP53; the disease is acute myeloid leukemia.